Get the Stockscreener App
37.18
2.44%
-0.93
After Hours:
37.18
Vera Therapeutics Inc Stock (VERA) Latest News
Wolfe Research Begins Coverage on Vera Therapeutics (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Upgraded at Wolfe Research - Defense World
Wolfe Research Initiates Coverage of Vera Therapeutics (VERA) with Outperform Recommendation - MSN
Vera Therapeutics initiated with an Outperform at Wolfe Research - MSN
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Wolfe Research Initiates Coverage on Vera Therapeutics (NASDAQ:VERA) - MarketBeat
Wolfe Research Initiates Coverage on Vera Therapeutics With Outperform Rating, $49 Price Target - Marketscreener.com
Vera Therapeutics (NASDAQ:VERA) Stock Price Up 4.9%Here's Why - MarketBeat
SG Americas Securities LLC Has $857,000 Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
The Goldman Sachs Group Begins Coverage on Vera Therapeutics (NASDAQ:VERA) - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
The Goldman Sachs Group Initiates Coverage on Vera Therapeutics (NASDAQ:VERA) - Defense World
SG Americas Securities LLC Increases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Trading (VERA) With Integrated Risk Controls - Stock Traders Daily
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
Goldman Sachs Initiates Vera Therapeutics at Buy With $58 Price Target -January 28, 2025 at 07:43 am EST - Marketscreener.com
Polycythemia Vera Pipeline 2024: Clinical Trials Overview, - openPR
Research Analysts Set Expectations for VERA FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts VERA FY2025 Earnings - MarketBeat
Top 3 Health Care Stocks That Could Blast Off This Quarter - Benzinga
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of “Buy” from Analysts - Defense World
Possible Bearish Signals With Vera Therapeutics Insiders Disposing Stock - Simply Wall St
Vera Therapeutics Releases Updated Corporate Presentation Following J.P. Morgan Healthcare Conference - Defense World
When the Price of (VERA) Talks, People Listen - Stock Traders Daily
JPMorgan Chase & Co. Decreases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Nephrotic Syndrome Market Set to Grow Substantially Through 2034, DelveInsight Projects | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squib - The Globe and Mail
Vera Therapeutics Getting Closer To Key Technical Benchmark - MSN
Head to Head Comparison: CannTrust (OTCMKTS:CNTTF) versus Vera Therapeutics (NASDAQ:VERA) - Defense World
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Awards New Employee Stock Options and RSUs Worth $42.19 Per Share - StockTitan
Vera Therapeutics Stocks Surge Amid Strategic Moves - TipRanks
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down Following Insider Selling - Defense World
What's Going On With Vera Therapeutics Stock?Vera Therapeutics (NASDAQ:VERA) - Benzinga
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down After Insider Selling - MarketBeat
Vera Therapeutics Highlights Atacicept Progress at Conference - TipRanks
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor - GlobeNewswire
Vera Therapeutics Secures Stanford's Novel B Cell Therapy VT-109 in Exclusive Deal - StockTitan
Vera Therapeutics CEO Marshall sells shares for $730,535 By Investing.com - Investing.com Australia
Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce Sells 17,500 Shares - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Trading Down 7.3%Should You Sell? - MarketBeat
Vera Therapeutics CEO Marshall sells shares for $730,535 - Investing.com
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
How to Take Advantage of moves in (VERA) - Stock Traders Daily
Is Vera Therapeutics The NEXT BIG THING? Stock Price Soars! - Truth or Fiction
Vera Therapeutics to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Franklin Resources Inc. Sells 5,859 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Certain Options of Vera Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2024. - Marketscreener.com
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):